摘要：The aim of this study was to identify factors affecting the pharmacokinetics of mycophenolic acid (MPA) and its 7- O -glucuronide (MPAG) in systemic lupus erythematosus (SLE) patients. Thirty-one SLE patients in remission maintenance phase treated with mycophenolate mofetil (median 1500 mg/d) and prednisolone and followed-up for up to 56 months (median 13 months) were enrolled. Creatinine clearance and metal medication were significant predictors accounting for interindividual variability in the dose-normalized predose plasma concentration (C0) of MPA (adjusted R 2=0.305, p =0.01) in a multivariate analysis. Dose-normalized MPAG C0 was significantly correlated with only creatinine clearance (adjusted R 2=0.135, p =0.03). The free fraction of MPA was significantly correlated with only serum albumin (adjusted R 2=0.700, p <0.01). The free fraction of MPAG was significantly correlated with serum albumin, metal medication, and age (adjusted R 2=0.598, p =0.02). In conclusion, renal function and co-administered metal influenced the pharmacokinetics of MPA and MPAG in SLE patients in remission maintenance phase.
